Evercore ISI analyst Vijay Kumar says that the report by Reuters saying Hologic signed a $4.1M contract with the U.S. Department of Human Health Services to develop its Procleix Zika blood screening test points to traction in Zika blood screening. While it is hard to quantify Hologic's revenue benefit, Kumar believes this could represent about 2c-3c of potential EPS benefit, assuming that Zika blood screening becomes part of the regular screening process. He has a Buy rating and $42 price target on the shares. This note corrects an earlier version to reflect the firm's Buy rating.